179 related articles for article (PubMed ID: 37086459)
21. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
22. [Immunotherapy of renal cell cancer].
Géczi L; Nagyiványi K; Maráz A
Magy Onkol; 2017 Jun; 61(2):126-131. PubMed ID: 28585613
[TBL] [Abstract][Full Text] [Related]
23. The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma.
Bersanelli M; Buti S; Rizzo M
Expert Rev Anticancer Ther; 2021 Apr; 21(4):401-412. PubMed ID: 33287612
[No Abstract] [Full Text] [Related]
24. [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies].
Ferrière JM; Wallerand H; Bernhard JC; Cornu JN; Rouprêt M; Ravaud A
Prog Urol; 2008 Jul; 18 Suppl 4():S88-91. PubMed ID: 18706377
[TBL] [Abstract][Full Text] [Related]
25. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
26. Combination of cabozantinib and immune checkpoint inhibitors in advanced renal cell carcinoma: update from the European Society for Medical Oncology 2020.
Sarkis J; Khalil N; Alkassis M
Future Oncol; 2021 Mar; 17(9):991-992. PubMed ID: 33533650
[No Abstract] [Full Text] [Related]
27. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
28. Systemic therapy of metastatic renal cell carcinoma: Review of the current literature.
Zerdes I; Tolia M; Tsoukalas N; Mitsis M; Kardamakis D; Pistevou-Gombaki K; Tsekeris P; Kyrgias G
Urologia; 2019 Feb; 86(1):3-8. PubMed ID: 30270773
[TBL] [Abstract][Full Text] [Related]
29. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
[TBL] [Abstract][Full Text] [Related]
30. Current State of Systemic Therapies for Advanced Renal Cell Carcinoma.
Gulati S; Vaishampayan U
Curr Oncol Rep; 2020 Feb; 22(3):26. PubMed ID: 32048058
[TBL] [Abstract][Full Text] [Related]
31. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
Umeyama Y; Shibasaki Y; Akaza H
Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479
[TBL] [Abstract][Full Text] [Related]
32. Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence.
Rizzo A; Rosellini M; Marchetti A; Mollica V; Massari F
Immunotherapy; 2021 Jun; 13(8):685-692. PubMed ID: 33823678
[TBL] [Abstract][Full Text] [Related]
33. Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options.
Schmidt A; Azad A; Goh J; Harris C; Joshua AM; Weickhardt A; Krieger L
Asia Pac J Clin Oncol; 2019 Nov; 15 Suppl 10():3-10. PubMed ID: 31762165
[TBL] [Abstract][Full Text] [Related]
34. Kidney Cancer: An Overview of Current Therapeutic Approaches.
Chowdhury N; Drake CG
Urol Clin North Am; 2020 Nov; 47(4):419-431. PubMed ID: 33008493
[TBL] [Abstract][Full Text] [Related]
35. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
[TBL] [Abstract][Full Text] [Related]
36. Update on immunotherapy for renal cancer.
Canales Rojas R
Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
[TBL] [Abstract][Full Text] [Related]
37. New drug therapies for advanced renal cell carcinoma.
Gore ME; Harrison ML; Montes A
Expert Rev Anticancer Ther; 2007 Jan; 7(1):57-71. PubMed ID: 17187520
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Drug Monitoring of Sunitinib in Gastrointestinal Stromal Tumors and Metastatic Renal Cell Carcinoma in Adults-A Review.
Demlová R; Turjap M; Peš O; Kostolanská K; Juřica J
Ther Drug Monit; 2020 Feb; 42(1):20-32. PubMed ID: 31259881
[TBL] [Abstract][Full Text] [Related]
39. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
40. Designing novel immunocombinations in metastatic renal cell carcinoma.
Santoni M; Massari F; Aurilio G; Mollica V; Cimadamore A; Lopez-Beltran A; Cheng L; Battelli N; Nolé F; Montironi R
Immunotherapy; 2020 Dec; 12(17):1257-1268. PubMed ID: 32998603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]